Laboratoires Servier
Laboratoires Servier, a prominent French pharmaceutical company, is headquartered in Suresnes, France. Founded in 1954, Servier has established itself as a key player in the global healthcare industry, with a strong presence in Europe, Asia, and Africa. The company focuses on innovative treatments in various therapeutic areas, including cardiology, diabetes, oncology, and neurology. Servier is renowned for its commitment to research and development, investing significantly in new drug discovery and development. Its core products, such as the antihypertensive medication Perindopril, exemplify the company's dedication to improving patient outcomes through unique formulations and comprehensive treatment solutions. With a robust portfolio and a reputation for quality, Laboratoires Servier continues to strengthen its market position, achieving notable milestones in both innovation and patient care.
DitchCarbon Score
How does Laboratoires Servier's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoires Servier's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoires Servier's reported carbon emissions
In 2024, Laboratoires Servier reported total greenhouse gas emissions of approximately 69,904,000 kg CO2e for Scope 1 and about 33,048,000 kg CO2e for Scope 2. This marks a decrease from 2023, where emissions were approximately 71,457,000 kg CO2e for Scope 1 and 36,432,000 kg CO2e for Scope 2. Over the past few years, Servier has demonstrated a commitment to reducing its carbon footprint, with a target to achieve a 25% reduction in absolute Scope 1 and 2 emissions by 2030, based on a 2016 baseline. Additionally, Servier aims for a 42% reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions by 2030, compared to the 2021/2022 levels. For the near term, they have set a goal of a 16% reduction in Scope 1 and 2 emissions and a 10% reduction in Scope 3 emissions by 2025, also relative to the 2021/2022 baseline. Servier's climate commitments are aligned with the Science Based Targets initiative (SBTi), which includes specific targets for Scope 3 emissions, such as a 25% reduction in emissions from capital goods, waste generated in operations, business travel, and employee commuting by 2030. Furthermore, they plan to engage key suppliers, representing 52% of emissions from purchased goods and services, to set their own science-based targets by 2024. Overall, Laboratoires Servier is actively working towards significant emissions reductions, demonstrating a proactive approach to climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,044,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,578,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratoires Servier is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
